The aim of this cohort analysis was to estimate IFN-β discontinuation rates among MS patients in the United States (US) receiving subcutaneous (sc) IFN β-1a three times a week (tiw), and to identify factors associated with stopping patterns according to time on treatment in a real-world setting, by using data from claims databases. This evidence concerns the gene IFNB1 and myeloid sarcoma.